Adults

For children 2 to 11 years with body weight < 25 kg: 2.5 ml (containing 2.5 mg Rupatadine) once daily. For children 2 to 11 years with body weight ≥ 25 kg: 5 ml (containing 5 mg Rupatadine) once daily. Adults and adolescents (12 years and older) usually take Rupatadine 10 mg tablets. If syrup is prescribed for adults/adolescents, it is typically 10 ml (containing 10 mg Rupatadine) once daily.

Elderly

No specific dose adjustment required for elderly patients with normal renal and hepatic function. Use with caution in elderly patients due to potential for age-related decline in renal/hepatic function.

Renal_impairment

Use with caution in patients with renal impairment due to lack of specific studies. Dosage adjustments may be considered based on clinical judgment, but no established guidelines exist for severe impairment.

Onset

Within 1-2 hours.

Excretion

Approximately 60.9% of the dose is excreted via feces and 34.6% via urine over 7 days, mainly as metabolites.

Half life

Approximately 5.9 hours.

Absorption

Rapidly absorbed after oral administration. Peak plasma concentration (Cmax) is reached approximately 0.5 to 1 hour after administration.

Metabolism

Extensively metabolized, mainly by hepatic CYP3A4, to desloratadine and other active/inactive metabolites.

CNS depressants

Concurrent use with CNS depressants (e.g., alcohol, sedatives) may enhance CNS depression. Avoid or use with caution.

Ketoconazole/Erythromycin

Co-administration with potent CYP3A4 inhibitors like ketoconazole or erythromycin may increase systemic exposure to rupatadine. Use with caution.